Applied DNA Sciences (NASDAQ:APDN) has completed
design qualification, production and shipment of five COVID-19 vaccine
candidates to Italy-based Takis Biotech, to support preclinical animal
testing that will begin immediately.
The vaccine candidates were produced by Company’s PCR-based LinearDNA manufacturing systems.
Preliminary testing of plasmid-based vaccine
templates shows strong immune responses, catalyzes testing of Linear
DNA-based constructs set to begin immediately.
The next step is to utilize these LinearDNA
candidates to inoculate mice whose sera will be tested for the presence
of antibodies that bind to purified Spike protein.
Those positive candidates will be tested for their ability to neutralize SARS-CoV-2.
The company intends to execute its cGMP plan to support human trials scheduled to begin this fall.
Shares are up 51% premarket.
https://seekingalpha.com/news/3560794-applied-dna-up-51-premarket-on-advancement-of-covidminus-19-vaccine-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.